Revised ADA and EASD hyperglycaemia guidance now available

By Editor
30th September 2022
Hypoglycaemia, Type 2 diabetes

Two leading diabetes organisations have unveiled new consensus on the management of hyperglycaemia in type 2 diabetes.

The American Diabetes Association® (ADA) and the European Association for the Study of Diabetes (EASD) has published new recommendations on how to improve equity of care and reviews on how social determinants of health impact the management of hyperglycaemia.

Presented at the 58th European Association for the Study of Diabetes (EASD) Annual Meeting 2022, the consensus update also pays attention to the importance of weight loss and the use of evidence from randomised controlled trials on glucose-lowering medications to support evidence on losing and gaining weight.

Dr Robert Gabbay, Chief Scientific and Medical Officer for the ADA, said: “We are excited to share an updated consensus report on the management of hyperglycaemia in type 2 diabetes.

“This is a wide-ranging consensus report that has several new features. It not only speaks of what needs to be done, but it also has a section on how to implement those changes.”

In June 2022, a first draft of the guidance was presented at ADA’s 82nd Scientific Sessions, allowing the authors to receive constructive feedback.

Delegates recommended that the report should focus more on person-centred care, equity of care and managing weight loss.

The revised consensus includes:

  • Various recommendations on physical activity and behaviours across 24 hours including sleep
  • Updates on glucose-lowering therapies – Advice on the use of oral GLP-1 receptor agonists (RAs), higher doses of dulaglutide and semaglutide, the GIP/GLP-1 RA class, and combination GLP-1 RA and insulin
  • Specific information on comorbid conditions, such as heart failure, heart disease and chronic kidney disease
  • Intersecting themes regarding person-centred care

The new guidance has been developed by a global committee of experts that include Dr John B. Buse, University of North Carolina School of Medicine, Dr Melanie J. Davies CBE, Leicester Diabetes Centre and their colleagues.

Dr Davies CBE said: “I was delighted to co-chair this consensus report. It was truly a diverse group. I believe it continues to put the person living with diabetes at the centre of all we do and has a greater focus on implementation so we make a difference to peoples lives.”

To access the ADA and EASD consensus update, click here.

Comments (0)